Unexpected immune reactions? Inability to achieve specificity? Scalability constraints slowing everything down? These concerns persist in biologics workflows. And that is precisely where the chimeric monoclonal antibody continues to retain its relevance. What Changed and What Didn’t Biologics have developed. Fully human antibodies are now more widely recognized. But hybrid antibodies are still worth considering. Why? Because they provide the perfect compromise. The chimeric m
